JP2012514997A5 - - Google Patents

Download PDF

Info

Publication number
JP2012514997A5
JP2012514997A5 JP2011545812A JP2011545812A JP2012514997A5 JP 2012514997 A5 JP2012514997 A5 JP 2012514997A5 JP 2011545812 A JP2011545812 A JP 2011545812A JP 2011545812 A JP2011545812 A JP 2011545812A JP 2012514997 A5 JP2012514997 A5 JP 2012514997A5
Authority
JP
Japan
Prior art keywords
monovalent antibody
recombinant monovalent
region
recombinant
antibody according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011545812A
Other languages
English (en)
Japanese (ja)
Other versions
JP5755148B2 (ja
JP2012514997A (ja
Filing date
Publication date
Priority claimed from EP09290029A external-priority patent/EP2210902A1/en
Application filed filed Critical
Publication of JP2012514997A publication Critical patent/JP2012514997A/ja
Publication of JP2012514997A5 publication Critical patent/JP2012514997A5/ja
Application granted granted Critical
Publication of JP5755148B2 publication Critical patent/JP5755148B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011545812A 2009-01-14 2010-01-13 組換え一価抗体 Active JP5755148B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09290029.9 2009-01-14
EP09290029A EP2210902A1 (en) 2009-01-14 2009-01-14 Recombinant monovalent antibodies
PCT/IB2010/000196 WO2010082136A1 (en) 2009-01-14 2010-01-13 Recombinant monovalent antibodies

Publications (3)

Publication Number Publication Date
JP2012514997A JP2012514997A (ja) 2012-07-05
JP2012514997A5 true JP2012514997A5 (enExample) 2013-02-28
JP5755148B2 JP5755148B2 (ja) 2015-07-29

Family

ID=40435756

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011545812A Active JP5755148B2 (ja) 2009-01-14 2010-01-13 組換え一価抗体

Country Status (5)

Country Link
US (2) US9587023B2 (enExample)
EP (2) EP2210902A1 (enExample)
JP (1) JP5755148B2 (enExample)
CA (2) CA2749627C (enExample)
WO (1) WO2010082136A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210902A1 (en) * 2009-01-14 2010-07-28 TcL Pharma Recombinant monovalent antibodies
US8785604B2 (en) * 2010-02-18 2014-07-22 Effimune Anti-CD28 humanized antibodies
WO2014054804A1 (ja) 2012-10-05 2014-04-10 協和発酵キリン株式会社 ヘテロダイマータンパク質組成物
EP3297672B1 (en) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
KR102530742B1 (ko) 2016-05-20 2023-05-09 하푼 테라퓨틱스, 인크. 단일 도메인 혈청 알부민 결합 단백질
HRP20251020T1 (hr) 2016-05-20 2025-10-24 Harpoon Therapeutics, Inc. Proteini s jednolančanim varijabilnim fragmentom koji vežu cd3
HUE065861T2 (hu) * 2016-08-26 2024-06-28 Sanofi Sa Szelektív könnyûlánc-párosítást elõsegítõ multispecifikus antitestek
JP7215997B2 (ja) 2016-11-23 2023-01-31 ハープーン セラピューティクス,インク. 前立腺特異的膜抗原(psma)を標的とする三重特異性タンパク質と使用方法
KR102275008B1 (ko) 2016-11-23 2021-07-13 하푼 테라퓨틱스, 인크. 전립선 특이 막 항원 결합 단백질
WO2018160754A2 (en) * 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
SG10202107880XA (en) 2017-05-12 2021-09-29 Harpoon Therapeutics Inc Mesothelin binding proteins
US10730954B2 (en) 2017-05-12 2020-08-04 Harpoon Therapeutics, Inc. MSLN targeting trispecific proteins and methods of use
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
CA3078969A1 (en) 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
MX2020012217A (es) 2018-05-14 2021-03-02 Harpoon Therapeutics Inc Porción de unión para activación condicional de moléculas de inmunoglobulina.
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CN119306844A (zh) 2018-09-25 2025-01-14 哈普恩治疗公司 Dll3结合蛋白及使用方法
WO2020232303A1 (en) 2019-05-14 2020-11-19 Harpoon Therapeutics, Inc. EpCAM BINDING PROTEINS AND METHODS OF USE
BR112022016550A2 (pt) 2020-02-21 2022-11-16 Harpoon Therapeutics Inc Proteínas de ligação a flt3 e métodos de uso
US11919958B2 (en) 2020-08-19 2024-03-05 Xencor, Inc. Anti-CD28 compositions
IL314993A (en) 2022-02-23 2024-10-01 Xencor Inc Anti-cd28 x anti-psma antibodies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7408041B2 (en) * 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
EP1345969B1 (fr) * 2000-12-26 2010-08-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anticorps anti-cd28
US7053202B2 (en) * 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
GB0230203D0 (en) * 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
PT1718677E (pt) * 2003-12-19 2012-07-18 Genentech Inc Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
EP1809583A2 (en) * 2004-11-01 2007-07-25 MedImmune, Inc. Ultra high throughput capture lift screening methods
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AR056142A1 (es) 2005-10-21 2007-09-19 Amgen Inc Metodos para generar el anticuerpo igg monovalente
NZ569988A (en) * 2006-02-01 2011-09-30 Cephalon Australia Pty Ltd Domain antibody construct which binds to human TNF-alpha and contains a modified hinge region sequence and a truncated CH1 domain
US20100255012A1 (en) * 2007-05-31 2010-10-07 Genmab A/S Recombinant fucose modified monovalent half-antibodies obtained by molecular engineering
US20110097339A1 (en) * 2008-07-18 2011-04-28 Domantis Limited Compositions monovalent for CD28 binding and methods of use
EP2210902A1 (en) * 2009-01-14 2010-07-28 TcL Pharma Recombinant monovalent antibodies
US8785604B2 (en) * 2010-02-18 2014-07-22 Effimune Anti-CD28 humanized antibodies

Similar Documents

Publication Publication Date Title
JP5755148B2 (ja) 組換え一価抗体
JP2020508655A5 (enExample)
RU2011116927A (ru) Антитела против интерлейкина 17 (ил-17) человека и их применение
JP2012501669A5 (enExample)
JP2022512684A5 (enExample)
IL275270A (en) Recombinant scavenger cell surface proteins
JP2015519055A5 (enExample)
RU2019100481A (ru) Биспецифические антитела-ингибиторы контрольных точек
JP2019031529A5 (enExample)
JP2017504578A5 (enExample)
RU2013140350A (ru) Антитела против человеческого il33r и их применение
HK1207575A1 (en) Bispecific asymmetric heterodimers comprising anti-cd3 constructs
FI3998285T3 (fi) Cd38:aan ja pd-l1:een sitoutuvia molekyylejä
JP2012501670A5 (enExample)
RU2012142231A (ru) Антитела против csf-1r человека и их применение
JP2019525738A5 (enExample)
JP2013529084A5 (enExample)
CA3139508A1 (en) Materials and methods for modulating t cell mediated immunity
JP2013545455A5 (enExample)
FI3561057T3 (fi) Anti-cd3-vasta-aine ja vasta-ainetta sisältäviä molekyylejä
JP2014518883A5 (enExample)
JP2012525829A5 (enExample)
RU2014114172A (ru) Легковыделяемые биспецифические антитела с природным иммуноглобулиновым форматом
NZ701825A (en) Heterodimeric antibody fc-containing proteins and methods for production thereof
JP2010536396A5 (enExample)